BioMarin Pharmaceutical Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 BioMarin Pharmaceutical Inc 公司

BioMarin Pharmaceutical Inc. (BioMarin) 是一家生物技术公司，致力于开发和商业化解决遗传病根源的疗法。BioMarin 的商业产品包括 Vimizim (elosulfase alpha)、Naglazyme (galsulfase)、Palynziq (pegvaliase-pqpz)、Brineura (cerliponase alfa)、Aldurazyme (laronidase)、Roctavian (valoctocogene roxaparvovec)、Kuvan (sapropterin dihydrochloride) 和 Voxzogo (vosoritide)。Vimizim 是一种酶替代疗法，用于治疗溶酶体贮积症 MPS IVA。Roctavian 是一种腺相关病毒 (AAV5) 载体基因疗法，旨在恢复重度血友病 A 患者的血浆因子 VIII 浓度。Voxzogo 是一种每日一次注射的 C 型利钠肽 (CNP) 类似物，用于治疗软骨发育不全。 Brineura 是一种重组人三肽基肽酶 1 (TPP1)，用于治疗患有 CLN2（一种巴顿病）的患者。

BioMarin Pharmaceutical Inc简介



公司代码BMRN

公司名称BioMarin Pharmaceutical Inc

上市日期Jul 23, 1999

CEOMr. Alexander Hardy

员工数量3040

证券类型Ordinary Share

年结日Jul 23

公司地址770 Lindaro Street

城市SAN RAFAEL

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编94901

电话14155066700

网址https://www.biomarin.com/

公司代码BMRN

上市日期Jul 23, 1999

CEOMr. Alexander Hardy

BioMarin Pharmaceutical Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-7.06%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

Dr. Athena M. Countouriotis, M.D.

Independent Director

8.83K

+305.05%

Ms. Barbara W. Bodem

Independent Director

8.83K

+305.05%

Ms. Elizabeth Mckey Anderson

Independent Director

--

Mr. Timothy Walbert

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-7.06%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

Voxzogo

221.39M

27.23%

Vimizim

215.42M

26.50%

Naglazyme

128.87M

15.85%

Palynziq

105.94M

13.03%

Aldurazyme

56.44M

6.94%

其他

84.92M

10.45%

地区USD

名称

营收

占比

United States

272.55M

33.53%

Europe

243.14M

29.91%

Rest of the world

142.74M

17.56%

Latin America

98.12M

12.07%

ALDURAZYME net product revenues marked by Sanofi

56.44M

6.94%

业务

地区

业务USD

名称

营收

占比

Voxzogo

221.39M

27.23%

Vimizim

215.42M

26.50%

Naglazyme

128.87M

15.85%

Palynziq

105.94M

13.03%

Aldurazyme

56.44M

6.94%

其他

84.92M

10.45%

股东统计

更新时间: 8月16日周六

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.84%

BlackRock Institutional Trust Company, N.A.

9.39%

PRIMECAP Management Company

8.21%

Dodge & Cox

7.86%

Viking Global Investors LP

6.40%

其他

58.30%

持股股东

占比

The Vanguard Group, Inc.

9.84%

BlackRock Institutional Trust Company, N.A.

9.39%

PRIMECAP Management Company

8.21%

Dodge & Cox

7.86%

Viking Global Investors LP

6.40%

其他

58.30%

股东类型

持股股东

占比

Investment Advisor

43.91%

Investment Advisor/Hedge Fund

40.30%

Hedge Fund

7.65%

Pension Fund

3.13%

Research Firm

1.58%

Sovereign Wealth Fund

1.23%

Bank and Trust

1.14%

Individual Investor

0.75%

Venture Capital

0.34%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

1304

191.42M

99.64%

-19.19M

2025Q2

1333

195.10M

101.61%

-16.01M

2025Q1

1355

191.53M

99.87%

-20.72M

2024Q4

1336

190.53M

99.88%

-17.50M

2024Q3

1308

188.26M

98.81%

-22.17M

2024Q2

1293

192.58M

101.18%

-14.21M

2024Q1

1278

194.24M

102.38%

-11.23M

2023Q4

1294

193.16M

102.42%

-3.22M

2023Q3

1275

188.66M

100.18%

-4.68M

2023Q2

1283

185.80M

98.76%

-8.08M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

18.91M

9.85%

-8.07K

-0.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

18.04M

9.39%

-79.52K

-0.44%

Jun 30, 2025

PRIMECAP Management Company

15.77M

8.21%

-2.00M

-11.26%

Jun 30, 2025

Dodge & Cox

15.11M

7.87%

+153.07K

+1.02%

Jun 30, 2025

Viking Global Investors LP

12.29M

6.4%

+1.49M

+13.78%

Jun 30, 2025

State Street Investment Management (US)

8.85M

4.61%

+384.66K

+4.55%

Jun 30, 2025

AQR Capital Management, LLC

5.58M

2.91%

+2.65M

+90.74%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.47M

1.81%

+43.19K

+1.26%

Jun 30, 2025

Millennium Management LLC

2.83M

1.48%

+2.16M

+319.74%

Jun 30, 2025

Rothschild & Co Asset Management Europe SCS

1.97M

1.03%

-20.00

-0.00%

Aug 31, 2025

持股ETF



更新时间: 10月6日周一

机构名称

占比

Invesco Biotechnology & Genome ETF

4.74%

Global X Genomics & Biotechnology ETF

3.43%

First Trust NYSE Arca Biotechnology Index Fund

3.25%

Goldman Sachs Future Health Care Equity ETF

2.85%

SPDR S&P Biotech ETF

2.37%

WealthTrust DBS Long Term Growth ETF

2.11%

Alger Russell Innovation ETF

1.9%

First Trust Health Care Alphadex Fund

1.82%

Pacer Lunt MidCap Multi-Factor Alternator ETF

1.71%

Virtus LifeSci Biotech Products ETF

1.69%

Invesco Biotechnology & Genome ETF

占比4.74%

Global X Genomics & Biotechnology ETF

占比3.43%

First Trust NYSE Arca Biotechnology Index Fund

占比3.25%

Goldman Sachs Future Health Care Equity ETF

占比2.85%

SPDR S&P Biotech ETF

占比2.37%

WealthTrust DBS Long Term Growth ETF

占比2.11%

Alger Russell Innovation ETF

占比1.9%

First Trust Health Care Alphadex Fund

占比1.82%

Pacer Lunt MidCap Multi-Factor Alternator ETF

占比1.71%

Virtus LifeSci Biotech Products ETF

占比1.69%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据